News about "Progression-Free Survival"

Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial

Roche's investigational KRAS G12C inhibitor divarasib demonstrated superior progression-free and overall survival over approved first-generation therapies in the Phase III Krascendo 1 trial, marking a significant advance in the treatment of previously treated KRAS G12C-mutated non-small cell lung cancer.

Progression-Free Survival | 04/07/2026 | By News Bureau |  177

BeOne Medicines Reports Positive Phase 3 Results for Brukinsa in First-Line Mantle Cell Lymphoma

BeOne Medicines has reported positive Phase 3 results from the MANGROVE trial, showing that Brukinsa combined with rituximab significantly improves progression-free survival in previously untreated mantle cell lymphoma.

Progression-Free Survival | 02/07/2026 | By News Bureau

Oncoinvent Reaches 50 Percent Enrollment Milestone in Phase 2 Trial of Ovarian Cancer Therapy Radspherin

Oncoinvent has reached the halfway enrollment point in its Phase 2 trial of Radspherin, an experimental alpha-radiation therapy for ovarian cancer patients with peritoneal metastases, as recruitment accelerates across multiple international clinical sites.

Progression-Free Survival | 20/06/2026 | By News Bureau |  142

Pfizer Launches Elranatamab in India for Relapsed or Refractory Multiple Myeloma

Pfizer has launched Elranatamab in India for adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have received at least four prior therapies. The BCMA-directed bispecific antibody is available as a fixed-dose subcutaneous injection, offering a novel treatment option for heavily pretreated multiple myeloma patients.

Progression-free Survival | 03/06/2026 | By News Bureau

Bristol Myers Squibb's Mezigdomide Cuts Disease Progression Risk by Over 50 Percent in Multiple Myeloma

Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.

Progression-Free Survival | 30/05/2026 | By News Bureau

Pfizer's LORBRENA Delivers 7-Year Progression-Free Survival in Advanced NSCLC

Pfizer reported 7-year results from the CROWN trial showing that LORBRENA achieved the longest Progression-Free Survival reported to date in advanced Non-Small Cell Lung Cancer (NSCLC), with 55 percent of patients remaining progression-free at 7 years and median progression-free survival not yet reached.

Progression-Free Survival | 30/05/2026 | By News Bureau |  178

Merck's Phase 3 TroFuse-005 Trial Shows Survival Benefit of Sac-TMT in Advanced Endometrial Cancer

Merck announced that its phase 3 TroFuse-005 trial evaluating investigational antibody-drug conjugate Sacituzumab Tirumotecan (sac-TMT) met primary endpoints of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.

Progression-free Survival | 19/05/2026 | By News Bureau |  124

Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.

Progression-Free Survival | 07/05/2026 | By News Bureau |  121

Talzenna Plus Xtandi Improve Progression-Free Survival in Metastatic Prostate Cancer

Talzenna plus Xtandi significantly improved Progression-Free Survival (PFS) in the phase-III TALAPRO-3 trial, reducing the risk of disease progression or death in HRR-mutated Metastatic Prostate Cancer, with a positive trend in Overall Survival (OS).

Progression-Free Survival | 21/03/2026 | By News Bureau |  113

Daiichi Sankyo Submits sNDA in Japan for Datroway in First-Line Metastatic TNBC

Daiichi Sankyo files supplemental application in Japan for Datroway as a first-line treatment for metastatic triple negative breast cancer based on phase III trial data.

Progression-Free Survival | 13/02/2026 | By News Bureau |  203